Safety and Efficacy of Single or Reduced Ports Laparoscopic Gastrectomy for Advanced Gastric Cancer (SPACE-01)

Study Overview
=================
Brief Summary
-----------------
The aim of this study is to verify the safety and efficacy of single or reduced ports laparoscopic gastrectomy for advanced gastric cancer.

Detailed Description
-----------------
Since two cases of single-incision laparoscopic gastrectomy in early gastric cancer were reported in 2011, the safety and efficacy of single-incision laparoscopic gastrectomy in early gastric cancer have been reported several times. Recently, the feasibility of laparoscopic single-incision gastrectomy in some advanced gastric cancer has already been reported. The total number of retrieved lymph nodes during gastric cancer surgery is one of the most important indicators for securing oncological safety and predicting the therapeutic effect in gastric cancer surgery. Therefore, in order to prospectively evaluate the efficacy of single-incision or reduced-port laparoscopic gastrectomy for advanced gastric cancer as an oncological operation, the purpose of this study is to evaluate the number of resected lymph nodes after D2 lymph node dissection in single-incision or reduced-port laparoscopic gastrectomy for advanced gastric cancer. All surgeries are performed as single-incision laparoscopic surgery using a 3-4 cm umbilical incision, and D2 lymph node dissection is performed according to the Japanese gastric cancer treatment guidelines 2018 by the Japanese Gastric Cancer Association. When an additional trocar is required, it is classified as reduced port laparoscopy when one additional trocar is added. For surgical assistance, including effective visual field development during surgery, a self intra-corporeal retractor (FJ clip®, or Internal organ retractor®) or an additional trocar (up to 1 trocar) could be used. An articulating laparoscopic surgical instrument (Artisential ®) can be used for safe access to difficult areas of the D2 lymph node dissection, such as the superior border of the pancreas. Before the end of the surgery, the surgeon evaluates the completeness of D2 lymph node dissection and radical resection of the primary tumor(R0 resection). If insufficient, the operation is converted to multi-port laparoscopic surgery or open surgery, and additional D2 lymph node dissection and tumor resection are performed, and those cases are recorded separately in the registry as multiport/open conversion.

Official Title
-----------------
Safety and Efficacy of Single or Reduced Ports Laparoscopic Gastrectomy for Advanced Gastric Cancer (SPACE-01) Phase II Clinical Trial

Conditions
-----------------
Gastric Cancer, Gastric Adenocarcinoma

Intervention / Treatment
-----------------
* Procedure: Single port or reduced ports laparoscopic distal gastrectomy and D2 lymph node dissection


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients who have confirmed that participants have advanced gastric cancer at clinical stage T2 or higher and who can undergo distal gastrectomy for primary gastric cancer who have consented to single-port and reduced-port laparoscopic gastric cancer surgery Patients diagnosed with locally advanced gastric cancer in which no enlarged lymph nodes were observed in the preoperative examination, or lymph node metastases confined to the left gastric artery or perigastric area were suspected. Those who have not been treated for systemic inflammatory disease before surgery Exclusion Criteria: Those who have previously had gastrectomy. Those who have a laparotomy except for appendectomy, cholecystectomy or cesarean section. Patients with clinical (preoperative or intraoperative) stage T4b accompanied by infiltration of surrounding organs Those with bulky lymph nodes (single nodules over 3 cm or multiple nodules over 1.5 cm) Patients with confirmed distant metastasis (M1) Severe liver cirrhosis Patients who is judged by the investigator to be inappropriate for this study Patients who are taking antithrombotic drugs, including antiplatelet drugs and anticoagulants, and cannot safely stop before surgery

Ages Eligible for Study
-----------------
Minimum Age: 19 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Single port or reduced ports<br>Single port or reduced ports laparoscopic distal gastrectomy and D2 lymph node dissection | Procedure: Single port or reduced ports laparoscopic distal gastrectomy and D2 lymph node dissection<br>* Single port or reduced ports laparoscopic distal gastrectomy and D2 lymph node dissection<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| number of retrieved lymph nodes | number of retrieved lymph nodes during operation | during operation | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| postoperative complications | Postoperative complications are problems that can happen after participants have had surgery but which were not intended. | 3 year | 
| Quality of life of the participants | The patient's quality of life is assessed using the widely used quality of life questionnaire (European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30), sto22) before surgery (within 1 month before the day of surgery), within 1 week after surgery, within 1 month after surgery, within 3 months after surgery, within 6 months after surgery, and within 12 months after surgery, respectively. | before surgery (within 1 month before the day of surgery), within 1 week after surgery, within 1 month after surgery, within 3 months after surgery, within 6 months after surgery, and within 12 months after surgery | 
| 3 year relapse-free survival | 3 year relapse-free survival | 3 year | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Gastric cancer, Gastric adenocarcinoma, Gastrectomy, Single port